# β2-agonist Versus Ipratropium Bromide Associated With β2-agonists in Chronic Obstructive Pulmonary Disease Exacerbation

> **NCT01944033** · PHASE3 · COMPLETED · sponsor: **University of Monastir** · enrollment: 250 (actual)

## Conditions studied

- Acute Exacerbation of Chronic Obstructive Airways Disease

## Interventions

- **DRUG:** Bricanyl/Iprovent
- **DRUG:** Bricanyl

## Key facts

- **NCT ID:** NCT01944033
- **Lead sponsor:** University of Monastir
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07
- **Primary completion:** 2016-07
- **Final completion:** 2017-01
- **Target enrollment:** 250 (ACTUAL)
- **Last updated:** 2018-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01944033

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01944033, "β2-agonist Versus Ipratropium Bromide Associated With β2-agonists in Chronic Obstructive Pulmonary Disease Exacerbation". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01944033. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*